Verastem Oncology announced the initial safety, pharmacokinetics and recommended Phase 2 dose in the RAMP 203 trial evaluating the safety, tolerability and efficacy of avutometinib in combination.
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Avutometinib + Sotorasib Combination Demonstrated Preliminary Efficacy with Confirmed Responses in both KRAS G12C Inhibitor Resistant and Naïve PatientsNo New Safety Signals Observed in Combination; Most Treatment-Related Adverse Events Mild to ModerateEnrollment of Patients Naïve to or Previously Treated with a KRA.
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.